Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reports that, on 12 March 2026, it repurchased 790,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,016.00p to 2,057.00p per share, with a volume‑weighted average price of 2,036.73p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 9,480,409 ordinary shares. Following this latest transaction, the company holds 249,371,503 shares in treasury and has 4,066,797,319 ordinary shares in issue, giving a total of 4,066,797,319 voting rights.
GSK states that, in line with DTR 5.5.1R, 6.13 per cent of its voting rights are now attributable to ordinary shares held in treasury.
GSK plc reported that several senior leaders acquired small amounts of equity through company share plans. On March 10, 2026, executives including the President, Europe; Chief Financial Officer; Group General Counsel; President, Corporate Development; President, Global Supply Chain; President, Global Affairs; CEO, ViiV Healthcare and President, Global Health; and the SVP & Company Secretary each acquired 12 Ordinary Shares of 31¼ pence at £20.7168 per share under GSK's Share Reward Plan on the London Stock Exchange.
In a separate transaction on March 9, 2026, President Maya Martinez-Davis acquired 2.150 notional American Depositary Shares at $55.5100 within her GSK Executive Supplemental Savings Plan account on the New York Stock Exchange.
GSK plc reports that on 11 March 2026 it repurchased 513,409 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought between 2,047.00p and 2,078.00p at a volume-weighted average price of 2,061.69p and will be held as treasury shares.
Since 17 February 2026, GSK has repurchased 8,690,409 shares. After this transaction, it holds 248,581,503 shares in treasury and has 4,067,587,319 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.11% of voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 505,000 ordinary shares of 31¼ pence each on 10 March 2026. The shares were bought at prices between 2,052.00p and 2,082.00p, with a volume-weighted average price of 2,066.69p per share.
The repurchased shares will be held as treasury shares as part of GSK’s existing share buyback programme under a non-discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has bought 8,177,000 shares in total under the programme.
After this transaction, GSK holds 248,068,094 shares in treasury and has 4,068,100,728 ordinary shares in issue, giving a total of 4,068,100,728 voting rights. The company confirms that treasury shares represent 6.10 per cent of its voting rights.
GSK plc reports that it bought back 516,000 of its ordinary shares on 9 March 2026 through BNP Paribas SA under its existing non-discretionary share buyback programme. The volume-weighted average price was 2,028.51p per share, within a range of 1,989.00p to 2,047.00p.
The shares purchased will be held as treasury shares. Since 17 February 2026, GSK has bought 7,672,000 ordinary shares under this programme. After this transaction, it holds 247,563,094 shares in treasury and has 4,068,605,728 ordinary shares in issue, which equals 4,068,605,728 voting rights.
GSK confirms that, following these purchases, the percentage of voting rights attributable to treasury shares is 6.08%, a figure shareholders may use when assessing notification thresholds under the UK Financial Conduct Authority’s disclosure and transparency rules.
GSK plc reported a change in its Board committee membership. Effective 9 March 2026, Elizabeth McKee Anderson has been appointed as a member of the Corporate Responsibility Committee. She will serve on this committee in addition to her existing roles on the Audit & Risk and Remuneration committees.
GSK plc has signed a licence agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis (PBC).
GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval, $20 million upon EU and UK approvals, and up to $270 million in sales-based milestones, along with tiered double-digit royalties on global net sales. Linerixibat has positive phase III GLISTEN data and is under regulatory review in several major markets but is not yet approved anywhere. The transaction remains subject to customary conditions, including regulatory clearances such as under the US Hart-Scott-Rodino Act.
GSK plc reports it repurchased 690,000 ordinary shares of 31¼ pence each on 06 March 2026 through BNP Paribas under its existing share buyback programme. The lowest price paid was 2,029.00p, the highest was 2,080.00p, and the volume‑weighted average price was 2,048.95p per share.
The purchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 7,156,000 ordinary shares. After this transaction, it holds 247,047,094 shares in treasury and has 4,069,121,728 ordinary shares in issue, which is also the total number of voting rights.
The company states that, in line with DTR 5.5.1R, treasury shares represent 6.07% of voting rights. The filing also provides a detailed schedule of purchases by trading venue and individual trades on the London Stock Exchange and CBOE Europe order books.
GSK plc has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing audited financial statements for the year ended 31 December 2025.
The report is available online on both GSK’s annual report website and the SEC’s website. A hard copy of the 2025 Annual Report and the Notice of Annual General Meeting is expected to be available on or about 25 March 2026, and shareholders can request free hard copies of the complete audited financial statements from GSK’s UK registrar or its US ADR depositary.